Decellularized vein as a potential scaffold for vascular tissue engineering.
OBJECTIVE
Current strategies to create small-diameter vascular grafts involve seeding biocompatible, compliant scaffolds with autologous vascular cells. Our purpose was to study the composition and strength of decellularized vein to determine its potential as a vascular tissue-engineering scaffold.


METHODS
Intact human greater saphenous vein specimens were decellularized by using sodium dodecyl sulfate (SDS). Residual cellular and extracellular matrix composition was studied with light and electron microscopy as well as immunohistochemistry. Burst and suture-holding strength was measured in vitro by insufflation and pull-through techniques. To assess initial handling and durability of decellularized vein in vivo, a canine model was developed wherein decellularized canine jugular veins were implanted as carotid interposition grafts in recipient animals. After two weeks of arterial perfusion, these grafts were studied with duplex imaging and histologic methods.


RESULTS
Human saphenous vein decellularized by using SDS was devoid of endothelial cells and >94% of the cells resident within the vein wall. Collagen morphology appeared unchanged, and elastin staining decreased only slightly. Basement membrane collagen type IV remained intact. Compared with fresh vein, decellularized vein had similar in vitro burst (2480 +/- 460 mm Hg vs 2380 +/- 620 mm Hg; P >.05) and suture-holding (185 +/- 30 gm vs 178 +/- 66 gm; P >.05) strength. Decellularized canine vein functioned well in vivo without dilation, anastomotic complication, or rupture over 2 weeks of arterial perfusion.


CONCLUSIONS
Vein rendered acellular with SDS has well-preserved extracellular matrix, basement membrane structure, and strength sufficient for vascular grafting. These properties suggest proof of concept for its use as a scaffold for further vascular tissue engineering.


CONCLUSIONS
The following research examines the creation of a new small-diameter bypass graft. It is clinically relevant to patients who need distal arterial bypass, coronary artery bypass, or hemodialysis access, but who do not have adequate autologous vein for their surgeries. Future investigations will involve further tissue engineering of this vascular scaffold (eg, autologous endothelial seeding of its lumen) and testing the clinical usefulness of the completed graft.
Schaner
Patrick J
PJ
Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA. paul.dimuzio@jefferson.edu
Martin
Niels D
ND
Tulenko
Thomas N
TN
Shapiro
Irving M
IM
Tarola
Nicholas A
NA
Leichter
Rhoda F
RF
Carabasi
R Anthony
RA
Dimuzio
Paul J
PJ
D000954:Antigens, Surface / Q000494:pharmacology; D001807:Blood Vessel Prosthesis; D005109:Extracellular Matrix / Q000187:drug effects; D006801:Humans; D012501:Saphenous Vein / Q000187:drug effects* / Q000503:physiopathology; D012967:Sodium Dodecyl Sulfate / Q000494:pharmacology; D023822:Tissue Engineering / Q000379:methods*
D000954:Antigens, Surface; D012967:Sodium Dodecyl Sulfate